The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation

Riccardo Taulli, Francesca Bersani, Valentina Foglizzo, Alessandra Linari, Elisa Vigna, Marc Ladanyi, Thomas Tuschl, Carola Ponzetto

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Many microRNAs (miRNAs), posttranscriptional regulators of numerous cellular processes and developmental events, are downregulated in tumors. However, their role in tumorigenesis remains largely unknown. In this work, we examined the role of the muscle-specific miRNAs miR-1 and miR-206 in human rhabdomyosarcoma (RMS), a soft tissue sarcoma thought to arise from skeletal muscle progenitors. We have shown that miR-1 was barely detectable in primary RMS of both the embryonal and alveolar subtypes and that both miR-1 and miR-206 failed to be induced in RMS cell lines upon serum deprivation. Moreover, reexpression of miR-206 in RMS cells promoted myogenic differentiation and blocked tumor growth in xenografted mice by switching the global mRNA expression profile to one that resembled mature muscle. Finally, we showed that the product of the MET proto-oncogene, the Met tyrosine-kinase receptor, which is overexpressed in RMS and has been implicated in RMS pathogenesis, was downregulated in murine satellite cells by miR-206 at the onset of normal myogenesis. Thus, failure of posttranscriptional modulation may underlie Met overexpression in RMS and other types of cancer. We propose that tissue-specific miRNAs such as miR-1 and miR-206, given their ability to modulate hundreds of transcripts and to act as nontoxic differentiating agents, may override the genomic heterogeneity of solid tumors and ultimately hold greater therapeutic potential than single gene-directed drugs.

Original languageEnglish
Pages (from-to)2366-2378
Number of pages13
JournalJournal of Clinical Investigation
Volume119
Issue number8
DOIs
Publication statusPublished - Aug 3 2009

Fingerprint

Rhabdomyosarcoma
MicroRNAs
Muscles
Growth
Neoplasms
Down-Regulation
Alveolar Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
Proto-Oncogene Proteins c-met
Muscle Development
Sarcoma
human MIRN206 microRNA
Carcinogenesis
Skeletal Muscle
Cell Line
Messenger RNA
Serum
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. / Taulli, Riccardo; Bersani, Francesca; Foglizzo, Valentina; Linari, Alessandra; Vigna, Elisa; Ladanyi, Marc; Tuschl, Thomas; Ponzetto, Carola.

In: Journal of Clinical Investigation, Vol. 119, No. 8, 03.08.2009, p. 2366-2378.

Research output: Contribution to journalArticle

Taulli, Riccardo ; Bersani, Francesca ; Foglizzo, Valentina ; Linari, Alessandra ; Vigna, Elisa ; Ladanyi, Marc ; Tuschl, Thomas ; Ponzetto, Carola. / The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. In: Journal of Clinical Investigation. 2009 ; Vol. 119, No. 8. pp. 2366-2378.
@article{5eaf09383b7c49508858d92c8d13a8fd,
title = "The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation",
abstract = "Many microRNAs (miRNAs), posttranscriptional regulators of numerous cellular processes and developmental events, are downregulated in tumors. However, their role in tumorigenesis remains largely unknown. In this work, we examined the role of the muscle-specific miRNAs miR-1 and miR-206 in human rhabdomyosarcoma (RMS), a soft tissue sarcoma thought to arise from skeletal muscle progenitors. We have shown that miR-1 was barely detectable in primary RMS of both the embryonal and alveolar subtypes and that both miR-1 and miR-206 failed to be induced in RMS cell lines upon serum deprivation. Moreover, reexpression of miR-206 in RMS cells promoted myogenic differentiation and blocked tumor growth in xenografted mice by switching the global mRNA expression profile to one that resembled mature muscle. Finally, we showed that the product of the MET proto-oncogene, the Met tyrosine-kinase receptor, which is overexpressed in RMS and has been implicated in RMS pathogenesis, was downregulated in murine satellite cells by miR-206 at the onset of normal myogenesis. Thus, failure of posttranscriptional modulation may underlie Met overexpression in RMS and other types of cancer. We propose that tissue-specific miRNAs such as miR-1 and miR-206, given their ability to modulate hundreds of transcripts and to act as nontoxic differentiating agents, may override the genomic heterogeneity of solid tumors and ultimately hold greater therapeutic potential than single gene-directed drugs.",
author = "Riccardo Taulli and Francesca Bersani and Valentina Foglizzo and Alessandra Linari and Elisa Vigna and Marc Ladanyi and Thomas Tuschl and Carola Ponzetto",
year = "2009",
month = "8",
day = "3",
doi = "10.1172/JCI38075",
language = "English",
volume = "119",
pages = "2366--2378",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation

AU - Taulli, Riccardo

AU - Bersani, Francesca

AU - Foglizzo, Valentina

AU - Linari, Alessandra

AU - Vigna, Elisa

AU - Ladanyi, Marc

AU - Tuschl, Thomas

AU - Ponzetto, Carola

PY - 2009/8/3

Y1 - 2009/8/3

N2 - Many microRNAs (miRNAs), posttranscriptional regulators of numerous cellular processes and developmental events, are downregulated in tumors. However, their role in tumorigenesis remains largely unknown. In this work, we examined the role of the muscle-specific miRNAs miR-1 and miR-206 in human rhabdomyosarcoma (RMS), a soft tissue sarcoma thought to arise from skeletal muscle progenitors. We have shown that miR-1 was barely detectable in primary RMS of both the embryonal and alveolar subtypes and that both miR-1 and miR-206 failed to be induced in RMS cell lines upon serum deprivation. Moreover, reexpression of miR-206 in RMS cells promoted myogenic differentiation and blocked tumor growth in xenografted mice by switching the global mRNA expression profile to one that resembled mature muscle. Finally, we showed that the product of the MET proto-oncogene, the Met tyrosine-kinase receptor, which is overexpressed in RMS and has been implicated in RMS pathogenesis, was downregulated in murine satellite cells by miR-206 at the onset of normal myogenesis. Thus, failure of posttranscriptional modulation may underlie Met overexpression in RMS and other types of cancer. We propose that tissue-specific miRNAs such as miR-1 and miR-206, given their ability to modulate hundreds of transcripts and to act as nontoxic differentiating agents, may override the genomic heterogeneity of solid tumors and ultimately hold greater therapeutic potential than single gene-directed drugs.

AB - Many microRNAs (miRNAs), posttranscriptional regulators of numerous cellular processes and developmental events, are downregulated in tumors. However, their role in tumorigenesis remains largely unknown. In this work, we examined the role of the muscle-specific miRNAs miR-1 and miR-206 in human rhabdomyosarcoma (RMS), a soft tissue sarcoma thought to arise from skeletal muscle progenitors. We have shown that miR-1 was barely detectable in primary RMS of both the embryonal and alveolar subtypes and that both miR-1 and miR-206 failed to be induced in RMS cell lines upon serum deprivation. Moreover, reexpression of miR-206 in RMS cells promoted myogenic differentiation and blocked tumor growth in xenografted mice by switching the global mRNA expression profile to one that resembled mature muscle. Finally, we showed that the product of the MET proto-oncogene, the Met tyrosine-kinase receptor, which is overexpressed in RMS and has been implicated in RMS pathogenesis, was downregulated in murine satellite cells by miR-206 at the onset of normal myogenesis. Thus, failure of posttranscriptional modulation may underlie Met overexpression in RMS and other types of cancer. We propose that tissue-specific miRNAs such as miR-1 and miR-206, given their ability to modulate hundreds of transcripts and to act as nontoxic differentiating agents, may override the genomic heterogeneity of solid tumors and ultimately hold greater therapeutic potential than single gene-directed drugs.

UR - http://www.scopus.com/inward/record.url?scp=68849118992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849118992&partnerID=8YFLogxK

U2 - 10.1172/JCI38075

DO - 10.1172/JCI38075

M3 - Article

C2 - 19620785

AN - SCOPUS:68849118992

VL - 119

SP - 2366

EP - 2378

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -